keyword
MENU ▼
Read by QxMD icon Read
search

phase 3 carcinoma

keyword
https://www.readbyqxmd.com/read/29676845/mir-490-3p-inhibits-autophagy-via-targeting-atg7-in-hepatocellular-carcinoma
#1
Yingliang Ou, Jiafa He, Yubin Liu
The miR-490-3p was transfected into HepG2 cells to explore the correlation between miR-490-3p and hepatocellular carcinoma cell proliferation, apoptosis, and autophagy and its downstream target gene ATG7. Then we could possibly provide a mechanism for the treatment of hepatocellular carcinoma. MiR-490-3p was screened out by fold change > 4 and P < 0.01 using gene microarray data. The expression level of miR-490-3p was tested by qRT-PCR and the prognosis analysis was achieved by using TCGA data...
April 20, 2018: IUBMB Life
https://www.readbyqxmd.com/read/29670371/knockdown-of-fibrous-sheath-interacting-protein-1-expression-reduces-bladder-urothelial-carcinoma-cell-proliferation-and-induces-apoptosis-via-inhibition-of-the-pi3k-akt-pathway
#2
Ming Sun, Zhaofu Chen, Shutao Tan, Caigang Liu, Wenyan Zhao
Background: FSIP1 plays a vital role in tumorigenesis and cancer progression. In bladder cancer, FSIP1 overexpression was associated with poor prognosis of bladder urothelial carcinoma. In this study, we investigated whether FSIP1 is essential in the progression of bladder cancer and the mechanism by which it mediates this effect. Methods: FSIP1 expression was knocked down in bladder cancer cells using lentiviral-mediated short hairpin RNA (shRNA). FSIP1 expression was detected using Western blotting, immunohistochemistry (IHC), and quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29669181/racial-disparity-in-oncologic-and-quality-of-life-outcomes-in-patients-with-locally-advanced-head-and-neck-squamous-cell-carcinomas-enrolled-in-a-randomized-phase-2-trial
#3
Margaret K Guerriero, Mary W Redman, Kelsey K Baker, Renato G Martins, Keith Eaton, Laura Q Chow, Rafael Santana-Davila, Christina Baik, Bernardo H Goulart, Sylvia Lee, Cristina P Rodriguez
BACKGROUND: To better understand patient-reported quality of life (PRQOL) for patients with head and neck cancer, PRQOL scores were collected in a clinical trial. METHODS: Patients were randomized to arm A (70 Gy of radiation with cisplatin) or arm B (70 Gy of radiation with cisplatin plus erlotinib at 150 mg daily). PRQOL scores were measured on days -7 (arm B only), 0, 30, and 180 with the University of Washington Quality of Life Questionnaire. Associations with clinical factors and outcomes were explored with linear mixed, logistic, and Cox regression models...
April 18, 2018: Cancer
https://www.readbyqxmd.com/read/29667066/population-exposure-response-analysis-of-cabozantinib-efficacy-and-safety-endpoints-in-patients-with-renal-cell-carcinoma
#4
Steven Lacy, Jace Nielsen, Bei Yang, Dale Miles, Linh Nguyen, Matt Hutmacher
BACKGROUND: In the phase III METEOR trial, tyrosine kinase inhibitor cabozantinib significantly improved progression-free survival (PFS), objective response rate (ORR), and overall survival compared to everolimus in patients with advanced renal cell carcinoma (RCC) who had received prior VEGFR inhibitor therapy. In METEOR, RCC patients started at a daily 60-mg cabozantinib tablet (Cabometyx™) dose but could reduce to 40- or 20-mg to achieve a tolerated exposure. OBJECTIVES AND METHODS: Exposure-response (ER) models were developed to characterize the relationship between cabozantinib at clinically relevant exposures in RCC patients enrolled in METEOR and efficacy (PFS and tumor response) and safety endpoints...
April 17, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29666026/cervical-cancer-state-of-the-science-from-angiogenesis-blockade-to-checkpoint-inhibition
#5
REVIEW
Lindsey E Minion, Krishnansu S Tewari
Vascular endothelial growth factor (VEGF) has emerged as a therapeutic target in several malignancies, including cervical cancer. Chemotherapy doublets combined with the fully humanized monoclonal antibody, bevacizumab, now constitute first-line therapy for women struggling with recurrent/metastatic cervical carcinoma. Regulatory approval for this indication was based on the phase III randomized trial, GOG 240, which demonstrated a statistically significant and clinically meaningful improvement in overall survival when bevacizumab was added to chemotherapy: 17...
March 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29663291/apatinib-a-review-in-advanced-gastric-cancer-and-other-advanced-cancers
#6
Lesley J Scott
Apatinib [AiTan™ (China); Rivoceranib® (global)] is a novel, small molecule, selective vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor and is the second anti-angiogenic drug to be approved in China for the treatment of advanced or metastatic gastric cancer. This article summarizes the pharmacological properties of apatinib and reviews its clinical use in chemotherapy-experienced patients with advanced gastric adenocarcinoma, including gastroesophageal adenocarcinoma (GEA), or with other advanced cancers such as non-small cell lung cancer (NSCLC), breast cancer, gynaecological cancers, hepatocellular carcinoma (HCC), thyroid cancer and sarcomas...
April 16, 2018: Drugs
https://www.readbyqxmd.com/read/29662541/cabozantinib-in-the-treatment-of-advanced-renal-cell-carcinoma-in-adults-following-prior-vascular-endothelial-growth-factor-targeted-therapy-clinical-trial-evidence-and-experience
#7
REVIEW
Susanne Osanto, Tom van der Hulle
Cabozantinib is an oral multitargeted tyrosine kinase inhibitor (TKI) that potently inhibits MET and AXL, both associated with poor prognosis in renal cell carcinoma (RCC), next to vascular endothelial growth factor receptor 2, KIT, FLT3 and RET. Chronic treatment with vascular endothelial growth factor receptor (VEGFR)-targeting sunitinib upregulates MET and AXL in RCC, indicating that cabozantinib may be particularly effective in patients with advanced RCC whose disease progressed on prior VEGFR-targeted treatment...
March 2018: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29644393/treatment-of-carcinoma-in-situ-of-the-urinary-bladder-with-an-alpha-emitter-immunoconjugate-targeting-the-epidermal-growth-factor-receptor-a-pilot-study
#8
Michael E Autenrieth, Christof Seidl, Frank Bruchertseifer, Thomas Horn, Florian Kurtz, Benedikt Feuerecker, Calogero D'Alessandria, Christian Pfob, Stephan Nekolla, Christos Apostolidis, Saed Mirzadeh, Jürgen E Gschwend, Markus Schwaiger, Klemens Scheidhauer, Alfred Morgenstern
PURPOSE: Patients with carcinoma in situ (CIS) of the bladder refractory to bacillus Calmette-Guérin (BCG) treatment are usually treated with cystectomy. Therefore, new treatment options with preservation of the urinary bladder are needed. The objective of the study was to investigate the feasibility, safety and efficacy of a novel targeted alpha-emitter immunotherapy for CIS after BCG treatment failure. METHODS: A pilot study was conducted in 12 patients (age range 64-86 years, ten men, two women) with biopsy-proven CIS of the bladder refractory to BCG treatment...
April 11, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29643063/evaluation-of-prexasertib-a-checkpoint-kinase-1-inhibitor-in-a-phase-ib-study-of-patients-with-squamous-cell-carcinoma
#9
David S Hong, Kathleen N Moore, Manish R Patel, Stefan C Grant, Howard A Burris, William N William, Suzanne Jones, Funda Meric-Bernstam, Jeffrey Infante, Lisa Golden, Wei Zhang, Ricardo Martinez, Sameera R Wijayawardana, Richard P Beckmann, Aimee Bence Lin, Cathy Eng, Johanna C Bendell
PURPOSE: Prexasertib, a checkpoint kinase 1 inhibitor, demonstrated single-agent activity in patients with advanced squamous cell carcinoma (SCC) in the dose-escalation portion of a Phase I study (NCT01115790). Monotherapy prexasertib was further evaluated in patients with advanced SCC. EXPERIMENTAL DESIGN: Patients were given prexasertib 105 mg/m2 as a 1-hour infusion on day 1 of a 14-day cycle. Expansion cohorts were defined by tumor and treatment line. Safety, tolerability, efficacy, and exploratory biomarkers were analyzed...
April 11, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29629800/comparison-of-visualization-rates-of-li-rads-version-2014-major-features-with-iv-gadobenate-dimeglumine-or-gadoxetate-disodium-in-patients-at-risk-for-hepatocellular-carcinoma
#10
Brian C Allen, Lisa M Ho, Tracy A Jaffe, Chad M Miller, Maciej A Mazurowski, Mustafa R Bashir
OBJECTIVE: The purpose of this study is to compare visualization rates of the major features covered by Liver Imaging Reporting and Data System (LI-RADS) version 2014 in patients at risk for hepatocellular carcinoma using either gadobenate dimeglumine or gadoxetate disodium IV contrast agent. MATERIALS AND METHODS: This retrospective study included liver MRI examinations performed with either gadobenate dimeglumine or gadoxetate disodium contrast enhancement. Using age, sex, underlying liver disease, and presence of cirrhosis, patients were placed into matched cohorts...
April 9, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29627502/juglone-induces-apoptosis-and-autophagy-via-modulation-of-mitogen-activated-protein-kinase-pathways-in-human-hepatocellular-carcinoma-cells
#11
Peng Wang, Chang Gao, Wei Wang, Li-Ping Yao, Jing Zhang, Sun-Dong Zhang, Ji Li, Shao-Hong Fang, Yu-Jie Fu
Juglone (JG), a naturally-occurring naphthoquinone of Manchurian walnut (Juglans mandshurica) was shown to inhibit proliferation in various tumor types. However, the molecular mechanisms of JG on the induction of apoptosis and autophagy in HepG2 cells have not been examined. Herein, we investigated that JG could inhibit cell proliferation by induction of G2/M phase arrest. Also, occurrence of apoptosis was closely related with loss of mitochondrial membrane potential, the changes of apoptosis-related proteins after treatment with JG...
April 6, 2018: Food and Chemical Toxicology
https://www.readbyqxmd.com/read/29627389/plasma-msept9-a-novel-circulating-cell-free-dna-based-epigenetic-biomarker-to-diagnose-hepatocellular-carcinoma
#12
Abderrahim Oussalah, Susann Rischer, Mouni Bensenane, Guillaume Conroy, Pierre Filhine-Tresarrieu, Renée Debard, Denise Forest-Tramoy, Thomas Josse, Dana Reinicke, Matthieu Garcia, Amandine Luc, Cédric Baumann, Ahmet Ayav, Valérie Laurent, Marcus Hollenbach, Cristina Ripoll, Rosa-Maria Guéant-Rodriguez, Fares Namour, Alexander Zipprich, Michael Fleischhacker, Jean-Pierre Bronowicki, Jean-Louis Guéant
BACKGROUND: Patients with cirrhosis are at high risk of hepatocellular carcinoma (HCC). The SEPT9 gene is a key regulator of cell division and tumor suppressor whose hypermethylation is associated with liver carcinogenesis. The primary aim of this study was to evaluate the diagnostic accuracy of a PCR-based assay for the analysis of SEPT9 promoter methylation in circulating cell-free DNA (mSEPT9) for diagnosing HCC among cirrhotic patients. METHODS: We report two phase II biomarker studies that included cirrhotic patients with or without HCC from France (initial study) and Germany (replication study)...
March 28, 2018: EBioMedicine
https://www.readbyqxmd.com/read/29625879/tivantinib-for-second-line-treatment-of-met-high-advanced-hepatocellular-carcinoma-metiv-hcc-a-final-analysis-of-a-phase-3-randomised-placebo-controlled-study
#13
Lorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, Marc Pracht, Vittorina Zagonel, Philippe Mathurin, Elena Rota Caremoli, Camillo Porta, Bruno Daniele, Luigi Bolondi, Vincenzo Mazzaferro, William Harris, Nevena Damjanov, Davide Pastorelli, María Reig, Jennifer Knox, Francesca Negri, Jörg Trojan, Carlos López López, Nicola Personeni, Thomas Decaens, Marie Dupuy, Wolfgang Sieghart, Giovanni Abbadessa, Brian Schwartz, Maria Lamar, Terri Goldberg, Dale Shuster, Armando Santoro, Jordi Bruix
BACKGROUND: Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. The aim of this phase 3 study was to confirm the results of the phase 2 trial. METHODS: We did a phase 3, randomised, double-blind, placebo-controlled study in 90 centres in Australia, the Americas, Europe, and New Zealand...
April 3, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29619118/epigenetic-modifications-in-kdm-lysine-demethylases-associate-with-survival-of-early-stage-nsclc
#14
Yongyue Wei, Junya Liang, Ruyang Zhang, Yichen Guo, Sipeng Shen, Li Su, Xihong Lin, Sebastian Moran, Åslaug Helland, Maria M Bjaanæs, Anna Karlsson, Maria Planck, Manel Esteller, Thomas Fleischer, Johan Staaf, Yang Zhao, Feng Chen, David C Christiani
Background: KDM lysine demethylase family members are related to lung cancer clinical outcomes and are potential biomarkers for chemotherapeutics. However, little is known about epigenetic alterations in KDM genes and their roles in lung cancer survival. Methods: Tumor tissue samples of 1230 early-stage non-small cell lung cancer (NSCLC) patients were collected from the five independent cohorts. The 393 methylation sites in KDM genes were extracted from epigenome-wide datasets and analyzed by weighted random forest (Ranger) in discovery phase and validation dataset, respectively...
2018: Clinical Epigenetics
https://www.readbyqxmd.com/read/29616562/avelumab-a-review-of-its-application-in-metastatic-merkel-cell-carcinoma
#15
Jocelyn Joseph, Chrystia Zobniw, Jennifer Davis, Jaime Anderson, Van Anh Trinh
OBJECTIVE: To summarize the clinical development of avelumab and its clinical relevance in metastatic Merkel cell carcinoma (MCC). DATA SOURCES: An English-language literature search using PubMed was performed using the terms avelumab, anti-PD-1, anti-PD-L1, and MCC from January of 1950 to March 2018. Data were also obtained from package inserts, meeting abstracts, and clinical registries. STUDY SELECTION/DATA EXTRACTION: All relevant published articles of avelumab were reviewed...
April 1, 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29615901/isoquercetin-as-an-adjunct-therapy-in-patients-with-kidney-cancer-receiving-first-line-sunitinib-quasar-results-of-a-phase-i-trial
#16
Carlo Buonerba, Pietro De Placido, Dario Bruzzese, Martina Pagliuca, Paola Ungaro, Davide Bosso, Dario Ribera, Simona Iaccarino, Luca Scafuri, Antonietta Liotti, Valeria Romeo, Michela Izzo, Francesco Perri, Beniamino Casale, Giuseppe Grimaldi, Francesca Vitrone, Arturo Brunetti, Daniela Terracciano, Alfredo Marinelli, Sabino De Placido, Giuseppe Di Lorenzo
Sunitinib is the most commonly prescribed drug for advanced renal cell carcinoma in the first-line setting and has been associated with multiple adverse events related to its on-and off-target effects, including hand and foot syndrome and fatigue. It was hypothesized that sunitinib-induced fatigue may be related to off target inhibition of the AMPK enzyme, which results in impairment of energy-producing processes at a systemic level. Quercetin is a naturally occurring flavonol with established AMPK-stimulating activity...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29602084/a-comprehensive-lc-ms-ms-method-validation-for-the-quantitative-investigation-of-37-fingerprint-phytochemicals-in-achillea-species-a-detailed-examination-of-a-coarctata-and-a-monocephala
#17
Mustafa Abdullah Yilmaz, Abdulselam Ertas, Ismail Yener, Mehmet Akdeniz, Oguz Cakir, Muhammed Altun, Ibrahim Demirtas, Mehmet Boga, Hamdi Temel
The current study aims to optimize and validate a comprehensive LC-MS/MS method for the quantification of 37 phytochemicals (15 phenolic acids, 17 flavonoids, 3 non-phenolic organic acids, 1 phenolic aldehyde and 1 benzopyrene) in Achillea species. Though Achillea species were chosen as real life samples, the current method is applicable to a wide range of plant species. The developed method was fully validated in terms of linearity, accuracy (recovery), inter-day and intra-day precision (repeatability), limits of detection and quantification (LOD/LOQ) and relative standard uncertainty (U% at 95% confidence level (k = 2))...
March 10, 2018: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29601890/the-silencing-of-replication-protein-a1-induced-cell-apoptosis-via-regulating-caspase-3
#18
Yuesheng Zhu, Yongdong Yi, Binglong Bai, Liyi Li, Tao You, Weijian Sun, Yaojun Yu
AIMS: Gastrointestinal cancers are a kind of deadly malignancy afflicting close to a million peoples worldwide. 5-Fluorouracil (5-Fu) is a main chemotherapeutic agent for cancer treatment. However, prolonged exposure of 5-Fu to cancer cells may cause chemoresistance and decrease the therapeutic potential of 5-Fu. MAIN METHODS: Replication protein A (RPA) is a component of the origin recognition complex. In our study, we explored the role of RPA1 in hepatocellular carcinoma cell SMMC-7721, gastric cancer cell SGC-7901 and colorectal cancer HT-29 via lentiviral particles infection...
March 27, 2018: Life Sciences
https://www.readbyqxmd.com/read/29600761/development-of-promising-thiopyrimidine-based-anti-cancer-and-antimicrobial-agents-synthesis-and-qsar-analysis
#19
Manal M Anwar, Yasmin M Syam, Eman R Kotb, Samia A Elseginy
New hybrids of thiopyrimidine-five/six heterocyclic rings were synthesized and in vitro evaluated for their antiproliferative activity against three human cancer cell lines, namely HCT116 (human colorectal carcinoma), PC-3 (human prostate adenocarcinoma) and HepG2 (human liver carcinoma) cell lines. The most potency was elicited by the target candidates against the viability of HCT116 cell lines, higher than the positive control 5-Fluorouracil (IC50 range; 0.11-0.49 µM, IC50, 5-FU; 1.10 µM). Cell cycle analysis and apoptosis activation revealed that compound 20 induced G2/M phase arrest and apoptosis in HCT116 cells...
March 29, 2018: Mini Reviews in Medicinal Chemistry
https://www.readbyqxmd.com/read/29587324/-immunotherapy-for-renal-cell-carcinoma-current-status
#20
Marc-Oliver Grimm, Susan Foller
Systemic treatment of metastatic renal cell carcinoma (mRCC) has substantially changed during the last 2 years due to approval of the immune-checkpoint inhibitor Nivolumab (Opdivo® ) and new multikinase inhibitors (Cabozantinib, Lenvatinib, Tivozanib). The german kidney tumor guideline strongly recommends Nivolumab and Cabozantinib as 2nd line treatments after prior VEGF targeted therapy. CheckMate 025, the prospective randomized trial which led to approval of Nivolumab demonstrated improved overall survival (26 month vs...
April 2018: Aktuelle Urologie
keyword
keyword
91255
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"